Literature DB >> 19713984

Hepatitis C: The role of new interferons in the era of STAT-C.

Rami Moucari, Patrick Marcellin.   

Abstract

More than 50% of patients infected with HCV genotype 1 fail respond to standard treatment with peginterferon plus ribavirin. potent treatment strategies are urgently needed to improve outcomes for such patients. novel interferons and specifically targeted antiviral therapy for HCV (STAT-C) represent promising strategies.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19713984     DOI： 10.1038/nrgastro.2009.141

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  9 in total

1.  High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.

Authors:  Rami Moucari; Marie-Pierre Ripault; Valérie Oulès; Michèle Martinot-Peignoux; Tarik Asselah; Nathalie Boyer; Ahmed El Ray; Dominique Cazals-Hatem; Dominique Vidaud; Dominique Valla; Marc Bourlière; Patrick Marcellin
Journal:  J Hepatol       Date:  2006-11-27       Impact factor: 25.083

2.  Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.

Authors:  Bruce R Bacon; Mitchell L Shiffman; Flavia Mendes; Reem Ghalib; Tarek Hassanein; Giuseppe Morelli; Shobha Joshi; Kenneth Rothstein; Paul Kwo; Norman Gitlin
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

3.  Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

Authors:  Adrian M Di Bisceglie; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; James E Everhart; Elizabeth C Wright; William M Lee; Anna S Lok; Herbert L Bonkovsky; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Kristin K Snow; Jules L Dienstag
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

4.  Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.

Authors:  Rami Moucari; Tarik Asselah; Dominique Cazals-Hatem; Hélène Voitot; Nathalie Boyer; Marie-Pierre Ripault; Rodolphe Sobesky; Michèle Martinot-Peignoux; Sarah Maylin; Marie-Hélène Nicolas-Chanoine; Valérie Paradis; Michel Vidaud; Dominique Valla; Pierre Bedossa; Patrick Marcellin
Journal:  Gastroenterology       Date:  2007-11-12       Impact factor: 22.682

5.  Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.

Authors:  Donald M Jensen; Patrick Marcellin; Bradley Freilich; Pietro Andreone; Adrian Di Bisceglie; Carlos E Brandão-Mello; K Rajender Reddy; Antonio Craxi; Antonio Olveira Martin; Gerlinde Teuber; Diethelm Messinger; James A Thommes; Andreas Tietz
Journal:  Ann Intern Med       Date:  2009-04-21       Impact factor: 25.391

6.  Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

Authors:  Mitchell L Shiffman; Adrian M Di Bisceglie; Karen L Lindsay; Chihiro Morishima; Elizabeth C Wright; Gregory T Everson; Anna S Lok; Timothy R Morgan; Herbert L Bonkovsky; William M Lee; Jules L Dienstag; Marc G Ghany; Zachary D Goodman; James E Everhart
Journal:  Gastroenterology       Date:  2004-04       Impact factor: 22.682

7.  Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin.

Authors:  Carroll B Leevy
Journal:  Dig Dis Sci       Date:  2008-01-25       Impact factor: 3.199

Review 8.  Hepatitis B and hepatitis C in 2009.

Authors:  Patrick Marcellin
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

9.  Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.

Authors:  Thierry Poynard; Massimo Colombo; Jordi Bruix; Eugene Schiff; Ruben Terg; Steven Flamm; Ricardo Moreno-Otero; Flair Carrilho; Warren Schmidt; Thomas Berg; Thomas McGarrity; E Jenny Heathcote; Fernando Gonçales; Moises Diago; Antonio Craxi; Marcelo Silva; Pierre Bedossa; Pabak Mukhopadhyay; Louis Griffel; Margaret Burroughs; Clifford Brass; Janice Albrecht
Journal:  Gastroenterology       Date:  2009-01-22       Impact factor: 22.682
  9 in total
  1 in total

1.  Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.

Authors:  Robert A Fridell; Dike Qiu; Chunfu Wang; Lourdes Valera; Min Gao
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.